Late relapsing mantle cell lymphoma showing preserved sensitivity to single-agent lenalidomide
| Autor: | Cristina Bagacean, Mihnea Zdrenghea, Jean-Christophe Ianotto, Corina Bocsan, Adrian Tempescul, Pierre-Yves Salaun |
|---|---|
| Přispěvatelé: | Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), CHRU Brest - Service d'Hématologie (CHU-Brest-Hemato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), LabEX IGO Immunothérapie Grand Ouest, CHRU Brest - Service de médecine nucléaire (CHU - BREST - Med Nucléaire), Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, 'Prof. Dr. Ion Chiricuta' Oncologic Insitute Cluj-Napoca |
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Oncology
medicine.medical_specialty MESH: Remission Induction health care facilities manpower and services Lymphoma Mantle-Cell Disease 03 medical and health sciences 0302 clinical medicine Recurrence Internal medicine hemic and lymphatic diseases medicine Humans Immunologic Factors Single agent Relapse IMiD Lenalidomide Aged MESH: Treatment Outcome MESH: Aged Hematology Mantle cell lymphoma MESH: Humans business.industry MESH: Immunologic Factors Remission Induction MESH: Thalidomide medicine.disease Thalidomide 3. Good health MESH: Recurrence Regimen Treatment Outcome 030220 oncology & carcinogenesis Immunology Refractory Mantle Cell Lymphoma [SDV.IMM]Life Sciences [q-bio]/Immunology MESH: Lymphoma Mantle-Cell business 030215 immunology medicine.drug |
| Zdroj: | International Journal of Hematology International Journal of Hematology, Springer Verlag, 2016, 104 (3), pp.400-2 |
| ISSN: | 0925-5710 |
| Popis: | International audience; Mantle cell lymphoma is a hematologic malignancy characterized by poor therapeutic outcomes. Immunomodulatory drugs are a focus of attention in this disease, especially for the elderly and frail patients not able to tolerate the typically intensive therapeutic approaches used in fitter patients. We here present the case of refractory mantle cell lymphoma of the elderly that achieved complete remission following the use of single-agent lenalidomide, and a second complete response to the same regimen on relapse 5 years later. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink